# A Study of VET3-TGI in Patients With Solid Tumors

> **NCT06444815** · PHASE1 · RECRUITING · sponsor: **KaliVir Immunotherapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Microsatellite Stable Colorectal Cancer
- Head and Neck Squamous Cell Carcinoma
- Cervical Cancer
- Kidney Cancer
- Renal Cell Carcinoma
- Melanoma Stage IV
- Merkel Cell Carcinoma of Skin
- Mesothelioma
- Non-small Cell Lung Cancer
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Urothelial Carcinoma Bladder
- Squamous Cell Carcinoma

## Interventions

- **DRUG:** VET3-TGI
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT06444815
- **Lead sponsor:** KaliVir Immunotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-16
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06444815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06444815, "A Study of VET3-TGI in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06444815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*